Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways.
Radiotherapy is one of the most widely used treatments for cancer; however, the development of tumor radioresistance is an ongoing problem. Agents that target tumor angiogenesis are being used in combination with radiotherapy to improve the therapeutic index without a clear understanding of how these agents may affect radiosensitization. This article discusses recently published studies that may shed some light on the underlying signaling mechanisms that are involved in the interactions of antiangiogenic agents with ionizing radiation.
Division of Experimental Radiation Oncology, Department of Radiation Oncology, Kimmel Cancer Center, Jefferson Medical College of Thomas Jefferson University, 111 South 11th Street, Philadelphia, PA 19107, USA.
Phyllis
P
Wachsberger
Randy
R
Burd
Adam P
AP
Dicker
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D006801:Humans; D009369:Neoplasms / Q000098:blood supply* / Q000532:radiotherapy*; D009389:Neovascularization, Pathologic / Q000532:radiotherapy*; D015398:Signal Transduction
D020533:Angiogenesis Inhibitors